Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chengcheng Gong

Showing results (31-40 of 46) with videos related to

Pageof 5
Sort By:
Scientific Reports|March 7, 2019
Cisplatin shows greater efficacy than gemcitabine when combined with nab-paclitaxel in metastatic triple-negative breast cancerYi Li, Yannan Zhao, Chengcheng Gong, et al.
Annals of Palliative Medicine|October 21, 2021
Phase II study of chidamide in combination with cisplatin in patients with metastatic triple-negative breast cancerYanchun Meng, Juan Jin, Chengcheng Gong, et al.
International Journal of General Medicine|May 19, 2021
Prediction of Pretreatment 18F-FDG-PET/CT Parameters on the Outcome of First-Line Therapy in Patients with Metastatic Breast CancerYi Li, Cheng Liu, Bibo Wang, et al.
Cancers|August 26, 2022
Temporal Heterogeneity of HER2 Expression and Spatial Heterogeneity of <sup>18</sup>F-FDG Uptake Predicts Treatment Outcome of Pyrotinib in Patients with HER2-Positive Metastatic Breast CancerChengcheng Gong, Cheng Liu, Zhonghua Tao, et al.
Therapeutic Advances in Medical Oncology|November 24, 2025
Development and validation of nomograms of outcomes for first-line platinum-based chemotherapy for metastatic triple-negative breast cancer: patient-level analysis of five prospective clinical trials in ChinaChengcheng Gong, Ting Li, Yifan Chen, et al.
Scientific Reports|July 28, 2017
A preliminary study of <sup>18</sup>F-FES PET/CT in predicting metastatic breast cancer in patients receiving docetaxel or fulvestrant with docetaxelChengcheng Gong, Zhongyi Yang, Yifei Sun, et al.
BMC Cancer|November 3, 2021
Phase II trail of nab-paclitaxel in metastatic breast cancer patients with visceral metastasesYizhao Xie, Chengcheng Gong, Jian Zhang, et al.
The Oncologist|November 16, 2020
Everolimus-Related Pneumonitis in Patients with Metastatic Breast Cancer: Incidence, Radiographic Patterns, and Relevance to Clinical OutcomeChengcheng Gong, Qin Xiao, Yi Li, et al.
Cancer Research and Treatment|March 14, 2023
Clinicopathological Analysis and Treatment of Adult Patients with Inflammatory Myofibroblastic Tumor: A 15-Year Single- Center StudyXin Liu, Chengcheng Gong, Jieyun Zhang, et al.
Scientific Reports|February 10, 2019
Treatment after Progression on Fulvestrant among Metastatic Breast Cancer Patients in Clinical Practice: a Multicenter, Retrospective StudyYizhao Xie, Yannan Zhao, Chengcheng Gong, et al.
Pageof 5

Showing results (31-40 of 46) with videos related to

Sort By:
Pageof 5
Scientific Reports|March 7, 2019
Cisplatin shows greater efficacy than gemcitabine when combined with nab-paclitaxel in metastatic triple-negative breast cancerYi Li, Yannan Zhao, Chengcheng Gong, et al.
Annals of Palliative Medicine|October 21, 2021
Phase II study of chidamide in combination with cisplatin in patients with metastatic triple-negative breast cancerYanchun Meng, Juan Jin, Chengcheng Gong, et al.
International Journal of General Medicine|May 19, 2021
Prediction of Pretreatment 18F-FDG-PET/CT Parameters on the Outcome of First-Line Therapy in Patients with Metastatic Breast CancerYi Li, Cheng Liu, Bibo Wang, et al.
Cancers|August 26, 2022
Temporal Heterogeneity of HER2 Expression and Spatial Heterogeneity of <sup>18</sup>F-FDG Uptake Predicts Treatment Outcome of Pyrotinib in Patients with HER2-Positive Metastatic Breast CancerChengcheng Gong, Cheng Liu, Zhonghua Tao, et al.
Therapeutic Advances in Medical Oncology|November 24, 2025
Development and validation of nomograms of outcomes for first-line platinum-based chemotherapy for metastatic triple-negative breast cancer: patient-level analysis of five prospective clinical trials in ChinaChengcheng Gong, Ting Li, Yifan Chen, et al.
Scientific Reports|July 28, 2017
A preliminary study of <sup>18</sup>F-FES PET/CT in predicting metastatic breast cancer in patients receiving docetaxel or fulvestrant with docetaxelChengcheng Gong, Zhongyi Yang, Yifei Sun, et al.
BMC Cancer|November 3, 2021
Phase II trail of nab-paclitaxel in metastatic breast cancer patients with visceral metastasesYizhao Xie, Chengcheng Gong, Jian Zhang, et al.
The Oncologist|November 16, 2020
Everolimus-Related Pneumonitis in Patients with Metastatic Breast Cancer: Incidence, Radiographic Patterns, and Relevance to Clinical OutcomeChengcheng Gong, Qin Xiao, Yi Li, et al.
Cancer Research and Treatment|March 14, 2023
Clinicopathological Analysis and Treatment of Adult Patients with Inflammatory Myofibroblastic Tumor: A 15-Year Single- Center StudyXin Liu, Chengcheng Gong, Jieyun Zhang, et al.
Scientific Reports|February 10, 2019
Treatment after Progression on Fulvestrant among Metastatic Breast Cancer Patients in Clinical Practice: a Multicenter, Retrospective StudyYizhao Xie, Yannan Zhao, Chengcheng Gong, et al.
Pageof 5